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Dear Editor,
Febrile neutropenia (FN) is a serious side effect of chemothera-
py, and even when it does not result in significant morbidity,
mortality, and costs, it normally leads to a delay in subsequent
chemotherapy treatments [1]. Suboptimal delivery of chemo-
therapy and reduced relative dose intensity (RDI) adversely af-
fects long-term cancer outcome and survival [2]. FN is a surro-
gate marker for infections during chemotherapy and is charac-
terized by an absolute neutrophil count (ANC) <1000/mmc and
a single body temperature of >38.3 °C or a sustained tempera-
ture of ≥38 °C for more than 1 h [1, 3]. Risk of FN is dependent
on both patient-specific factors (e.g., type of cancer, disease
stage, co-morbid conditions, and age) and the myelotoxicity of
the chemotherapy regimen. Once an episode of FN occurs, the
risk of FN increases in subsequent chemotherapy cycles [4].
Recombinant granulocyte colony-stimulating factors (G-
CSFs) have been developed to stimulate proliferation and dif-
ferentiation of neutrophils in patients receiving chemotherapy.
The American Society of Clinical Oncology (ASCO) and
the National Comprehensive Cancer Network (NCCN) rec-
ommend the use of G-CSF as primary prophylaxis (PP) when
the overall FN risk is greater than 20 % following myelosup-
pressive chemotherapy, and secondary prophylaxis (SP) fol-
lowing FN or a dose-limiting neutropenic events [4, 5].
Pegfilgrastim is a pegylated long-acting recombinant form
of G-CSF which extends the half-life, requiring less frequent
dosing than non-pegylated G-CSF [6]. It is indicated to de-
crease the incidence of infection, as manifested by FN, in
patients with non-myeloid malignancies receiving myelosup-
pressive chemotherapy associated with a clinically significant
incidence of FN [5]. Pegfilgrastim is cleared via a neutrophil-
mediated system and requires only a single dose administered
subcutaneously once per chemotherapy cycle [6–8].
Multiple myeloma (MM) in advanced phases of disease may
be managed by regimens combining agents not frequently
employed in early phases of treatment (e.g., anthracyclines,
alkylating agents, etc), which have significant myelotoxicity.
Bendamustine is a bifunctional alkylating agent that produces
both single and double strand breaks in DNA, which has shown
good results in association with bortezomib and dexamethasone
in heavily pretreated patients [9], but in this schedule
myelotoxicity is themainexpectedsideeffect [10]. In thiscontext,
G-CSFs are often necessary to warrant an effective treatment,
counteracting the risks of febrile neutropenia. Their use is bound
to frequent evaluation of neutrophil counts which may not be
easily performed by patients in home care. Avoiding severe neu-
tropenia by prophylactic long-acting G-CSF, as pegfilgrastim,
seems particularly useful in this setting of patients.
The objective of this retrospective study was to evaluate the
efficacy and safety of pegfilgrastim in relapsed and refractory
MM patients, in treatment with courses of bendamustine-
bortezomib-dexamethasone (BVD), in order to determine
whether primary prophylaxis with pegfilgrastim is more effec-
tive than that with filgrastim [6, 11–13] in terms of incidence
of chemotherapy disruptions due to FN, days of hospitaliza-
tion, and G-CSF-related extra-hematological side effects.
Methods
FromDecember 2012 to February 2016, 47 patients have been
considered (25 male and 22 female) with a median age of
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61.3 years (range 37–83) affected by relapsed and refractory
MM, treated with several lines of treatments (median 6, r. 2–
11), and refractory to the drugs previously received, who were
treated with monthly courses of BVD (bendamustine 90 mg/
sqm i.v. days 1 and 2; bortezomib 1 mg/sqm s.c. days 1, 4, 8,
and 11; and dexamethasone 20 mg per os days 1, 2, 4, 5, 8, 9,
11, and 12, until progression).
All treatments were performed in our outpatient unit.
Twenty-four consecutive patients received pegfilgrastim
(6 mg) subcutaneously with a single administration on day
+4, as primary prophlyaxis, and they were compared to a
historical group of twenty-three consecutive patients in which
filgrastim (5 μg/kg/day for at least 3 days) had been given, as
primary prophylaxis Bon demand,^ if neutrophils count was
<1000 × 109 cells/L.
All patients performed blood counts twice weekly and re-
ceived, from day +8 to day +19, considering Bday +1^ the day
in which the chemotherapy protocol starts, prophylactic oral
quinolones and anti-fungal drugs.
Results
In filgrastim group, twenty-three consecutive patients, previ-
ously treated with several lines of treatments (median 6, r. 3–
11) with a median age of 60.7 years (r. 37–78) have been
considered. Nadir neutropenia was registered after a median
of 9.1 days (r.8–15), with maximum duration of 13 days (me-
dian 9.4 days, r. 7–13); median of nadir neutrophil count was
1.15 × 109 cells/L (range 0.3–1.5 × 109 cells/L). Median num-
ber of filgrastim administrations was 4.2 (r. 3–6). Patients have
been evaluated after at least three courses of therapy (r. 3–6).
Filgrastim was well tolerated in all patients; main side effects
were mild fever and bone pain (6/23, 26 %), treated success-
fully with paracetamol. Three hospitalizations for pneumonia
were needed during filgrastim (median days of hospitalization
15, range 8–19); the patients received intravenous antibiotic
treatment with resolution of infectious episodes. Four patients
(4/23, 17.3 %) disrupted chemotherapy schedules because of
neutropenia.
In pegfilgrastim group, twenty-four consecutive patients,
previously treated with several lines of treatments (median 6,
r. 2–10) with a median age of 62.1 years (r. 43–83) have been
considered. Nadir neutropenia, registered at day +11, was
1.484 × 109 cells/L (range 1.04–2.33 × 109 cells/L). During
pegfilgrastim, neutropenia, when present, was shorter than
during filgrastim treatment, never longer than 8 days (median
5.9 days, r. 4–8), with a consequent reduction of neutropenia-
related infections. Only four patients (16.6 %) needed, after
pegfilgrastim, a supplement of three administrations of
filgrastim. Patients have been evaluated after at least three
courses of therapy (r. 3–6). Apart from the advantage of
mono-administration, pegfilgrastim was well tolerated in all
patients; main side effects were mild fever and bone pain
(3/24, 12.5 %), treated successfully with paracetamol.
Moreover, no hospital izat ion was needed during
pegfilgrastim. Only two patients (2/24, 8.3 %) disrupted che-
motherapy schedules because of neutropenia.
In Italy, the cost of filgrastim 30-MU vial is 95.18–127.95
euro (depending from producer), while the cost of
pegfilgrastim 6 mg is 1.489.50 euro. However, this cost has
to be considered together with that of hospitalizations, antibi-
otic usage, and disruptions of scheduled chemotherapy
treatments.
Thus, pegfilgrastim was significantly associated with fewer
incidence rate of FN-related chemotherapy disruptions
(17.3 % in filgrastim group vs. 8.3 % in pegfilgrastim group,
p = 0.3534 by χ2 test), fewer days of hospitalization due to
FN (median number 15 days in filgrastim group vs. 0 in the
pegfilgrastim group), and fewer G-CSF-related extra-
hematological side effects (26 % in filgrastim group vs.
12.5 % in pegfilgrastim group, p = 0.2987 by χ2 test), with
consequent improvement of quality of life. However, statisti-
cal comparison of the two groups (by χ2 test) was not prop-
erly feasible because of the very small sample size.
Conclusions
In conclusions, in patients affected by relapsed and refractory
MM, treated with bendamustine-bortezomib-dexamethasone,
primary prophylaxis with pegfilgrastim seems to reduce the
incidence of chemotherapy disruptions due to FN, and the
days of hospitalization. Moreover, it is better tolerated and
may increase the opportunity tomaintain the planned schedule
of treatment. These results make pegfilgrastim and advanta-
geous option in most cases, both in terms of cost-effectiveness
and of quality of life. These preliminary observations need to
be validated by controlled clinical trials, involving a larger
number of patients.
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